JP5462168B2 - Ｎ−（５−ｔｅｒｔ−ブチル−イソオキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール−２−イル］フェニル｝ウレアを含む固形、その組成物、及びその用途 - Google Patents

Ｎ−（５−ｔｅｒｔ−ブチル−イソオキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール−２−イル］フェニル｝ウレアを含む固形、その組成物、及びその用途 Download PDF

Info

Publication number
JP5462168B2
JP5462168B2 JP2010525832A JP2010525832A JP5462168B2 JP 5462168 B2 JP5462168 B2 JP 5462168B2 JP 2010525832 A JP2010525832 A JP 2010525832A JP 2010525832 A JP2010525832 A JP 2010525832A JP 5462168 B2 JP5462168 B2 JP 5462168B2
Authority
JP
Japan
Prior art keywords
compound
certain embodiments
salt
hcl salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010525832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539237A (ja
JP2010539237A5 (enExample
Inventor
バグワット、シュリパド
ライ、ウェイ
ペアレント、ステファン、ディー．
ロウ、メラニー、ジェイ．
シュワルツ、アラン
スモレンスカヤ、バレリヤ、エヌ．
Original Assignee
アムビト ビオスシエンセス コルポラチオン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムビト ビオスシエンセス コルポラチオン filed Critical アムビト ビオスシエンセス コルポラチオン
Publication of JP2010539237A publication Critical patent/JP2010539237A/ja
Publication of JP2010539237A5 publication Critical patent/JP2010539237A5/ja
Application granted granted Critical
Publication of JP5462168B2 publication Critical patent/JP5462168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
JP2010525832A 2007-09-19 2008-09-19 Ｎ−（５−ｔｅｒｔ−ブチル−イソオキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール−２−イル］フェニル｝ウレアを含む固形、その組成物、及びその用途 Active JP5462168B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99463507P 2007-09-19 2007-09-19
US60/994,635 2007-09-19
PCT/US2008/010884 WO2009038757A2 (en) 2007-09-19 2008-09-19 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Publications (3)

Publication Number Publication Date
JP2010539237A JP2010539237A (ja) 2010-12-16
JP2010539237A5 JP2010539237A5 (enExample) 2011-10-27
JP5462168B2 true JP5462168B2 (ja) 2014-04-02

Family

ID=40468693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010525832A Active JP5462168B2 (ja) 2007-09-19 2008-09-19 Ｎ−（５−ｔｅｒｔ−ブチル−イソオキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール−２−イル］フェニル｝ウレアを含む固形、その組成物、及びその用途

Country Status (20)

Country Link
US (2) US8883783B2 (enExample)
EP (1) EP2201018B1 (enExample)
JP (1) JP5462168B2 (enExample)
KR (2) KR20150104231A (enExample)
CN (1) CN101868465B (enExample)
AR (1) AR068528A1 (enExample)
AU (1) AU2008302744B2 (enExample)
BR (1) BRPI0816904B8 (enExample)
CA (1) CA2696776C (enExample)
CY (1) CY1117583T1 (enExample)
DK (1) DK2201018T3 (enExample)
ES (1) ES2573292T3 (enExample)
HR (1) HRP20160520T1 (enExample)
HU (1) HUE027982T2 (enExample)
IL (1) IL203926A (enExample)
MX (1) MX2010002295A (enExample)
PL (1) PL2201018T3 (enExample)
SI (1) SI2201018T1 (enExample)
TW (1) TWI437988B (enExample)
WO (1) WO2009038757A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101449057B1 (ko) 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
BRPI0816904B8 (pt) 2007-09-19 2021-12-07 Ambit Biosciences Corp Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida
AU2008325141B2 (en) * 2007-11-08 2014-03-20 Ambit Biosciences Corp. Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
CN104447801A (zh) 2009-11-05 2015-03-25 埃姆比特生物科学公司 用于制备咪唑并[2,1-b][1,3]苯并噻唑衍生物的方法
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
CN103172648B (zh) * 2011-12-20 2016-05-25 上海迪诺医药科技有限公司 三杂环衍生物、制备方法及应用
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
AU2018299536B2 (en) * 2017-07-13 2022-06-02 Sunshine Lake Pharma Co., Ltd. Salt of substituted urea derivative and use thereof in medicine
US11634442B2 (en) * 2017-07-18 2023-04-25 Basf Se Methods for the purification of L-glufosinate
CN110763544A (zh) * 2019-09-20 2020-02-07 南京聚谱检测科技有限公司 一种激光剥蚀样品制靶用快干可精磨粘合剂
CN111413421A (zh) * 2020-02-20 2020-07-14 广东电科院能源技术有限责任公司 污泥燃烧后灰尘中氯离子含量的测试方法、控制方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129432C (enExample) 1964-02-29
NL129626C (enExample) 1964-04-08
US3210370A (en) 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en) 1980-03-07 1982-10-19 Eastman Kodak Company Indoline coupled isothiazole azo dyes
JPS56138196A (en) 1980-03-29 1981-10-28 Yamanouchi Pharmaceut Co Ltd Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en) 1980-08-22 1982-03-06 Yamanouchi Pharmaceut Co Ltd Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en) 1981-03-12 1982-09-14 Yamanouchi Pharmaceut Co Ltd Imidazo(2,1-b)benzothiazole derivative
US4464384A (en) 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
JPS58109491A (ja) * 1981-12-23 1983-06-29 Yamanouchi Pharmaceut Co Ltd ２−フエニルイミダゾ〃２，１−ｂ「あ」ベンゾチアゾ−ル誘導体
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US4880824A (en) 1987-09-21 1989-11-14 Ortho Pharmaceutical Corporation Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr) 1991-07-19 1993-01-20 Synthelabo Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja) 1991-10-17 1993-04-30 Konica Corp 新規な写真用カプラー
ES2126636T3 (es) 1992-05-19 1999-04-01 Adir Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
FR2699920B1 (fr) 1992-12-24 1995-02-10 Synthelabo Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
FR2700546B1 (fr) 1993-01-15 1995-02-17 Synthelabo Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr) 1994-07-13 1996-08-09 Synthelabo Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
JP3178843B2 (ja) 1995-03-13 2001-06-25 日研化学株式会社 イミダゾチアゾール化合物
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
US6127387A (en) 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
FR2759698B1 (fr) 1997-02-20 1999-03-19 Synthelabo Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
JP4437270B2 (ja) 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de) 1999-02-09 2000-08-10 Bayer Ag Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja) 1999-10-29 2001-07-17 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
CA2415815A1 (en) 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2003031587A2 (en) 2001-10-09 2003-04-17 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US20040127719A1 (en) 2002-03-08 2004-07-01 Kexin Yang Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
MXPA05005474A (es) 2002-11-25 2005-07-25 Pharmacia Corp Acidos y amidas heteroarilsulfonilmetil hidroxamicos y su uso como inhibidores de proteasas.
WO2004058758A1 (en) 2002-12-18 2004-07-15 Mallinckrodt Inc. Synthesis of heteroaryl acetamides
KR100647583B1 (ko) 2003-10-07 2006-11-17 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
KR101449057B1 (ko) * 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
BRPI0816904B8 (pt) 2007-09-19 2021-12-07 Ambit Biosciences Corp Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida
AU2008325141B2 (en) 2007-11-08 2014-03-20 Ambit Biosciences Corp. Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease

Also Published As

Publication number Publication date
EP2201018B1 (en) 2016-03-16
KR20150104231A (ko) 2015-09-14
KR101572701B1 (ko) 2015-11-27
US20090131426A1 (en) 2009-05-21
AU2008302744B2 (en) 2014-01-30
US20150238499A1 (en) 2015-08-27
WO2009038757A3 (en) 2009-05-28
AU2008302744A1 (en) 2009-03-26
HUE027982T2 (en) 2016-11-28
AR068528A1 (es) 2009-11-18
ES2573292T9 (es) 2016-07-08
CA2696776A1 (en) 2009-03-26
CY1117583T1 (el) 2017-04-26
BRPI0816904B1 (pt) 2021-08-10
CN101868465B (zh) 2013-12-25
CN101868465A (zh) 2010-10-20
ES2573292T3 (es) 2016-06-07
MX2010002295A (es) 2010-03-22
KR20100061734A (ko) 2010-06-08
TWI437988B (zh) 2014-05-21
SI2201018T1 (sl) 2016-09-30
DK2201018T3 (en) 2016-05-17
JP2010539237A (ja) 2010-12-16
TW200920360A (en) 2009-05-16
HRP20160520T1 (hr) 2016-07-29
US8883783B2 (en) 2014-11-11
WO2009038757A2 (en) 2009-03-26
CA2696776C (en) 2015-12-15
BRPI0816904B8 (pt) 2021-12-07
EP2201018A2 (en) 2010-06-30
PL2201018T3 (pl) 2016-11-30
US9585892B2 (en) 2017-03-07
BRPI0816904A2 (pt) 2015-03-17
IL203926A (en) 2016-02-29

Similar Documents

Publication Publication Date Title
JP2010539237A (ja) Ｎ−（５−ｔｅｒｔ−ブチル−イソオキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール−２−イル］フェニル｝ウレアを含む固形、その組成物、及びその用途
JP6381016B2 (ja) 選択的ｃｄｋ４／６阻害剤の固体形態
TWI288750B (en) Isethionate salt of a selective CDK4 inhibitor
JP7561240B2 (ja) ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法
CN107531682A (zh) B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
CN110650963A (zh) (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂*-9-基)氨基)丙酰胺的多晶型物和固体形式及其制备方法
JP5758399B2 (ja) 化合物、その一定の新形態、その医薬組成物ならびに製剤化および使用の方法
CN105294717B (zh) 一种egfr抑制剂的盐、晶型及其用途
CN111655698A (zh) 4-氨基-n-(1-((3-氯-2-氟苯基)氨基)-6-甲基异喹啉-5-基)噻吩并[3，2-d]嘧啶-7-甲酰胺的盐及其结晶型
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
CN111303024B (zh) 一种喹啉结构的pan-KIT激酶抑制剂及其用途
AU2017239301A1 (en) Crystalline forms of hydrochloride of drug for treating or preventing JAK-associated disease and preparation method thereof
CN111138426B (zh) 吲唑类激酶抑制剂及其用途
HK40115548A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
CN103270030B (zh) 吡唑基氨基喹唑啉的氢溴酸盐
WO2013130600A1 (en) Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
JP2025511099A (ja) Ｎ－（５－（（６，７－ジメトキシキノリン－４－イル）オキシ）ピリジン－２－イル）－１－プロピル－４－（２，２，２－トリフルオロエトキシ）－１ｈ－ピラゾール－３－カルボキサミド塩酸塩の新たな形態

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140116

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5462168

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153